54 results match your criteria: "University Heart Center Freiburg · Bad Krozingen[Affiliation]"
Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial.
Circ Cardiovasc Interv
February 2015
From the Department of Cardiology, Bern University Hospital, Bern, Switzerland (S.W.); Städtische Kliniken Neuss, Lukaskrankenhaus GmbH, Neuss, Germany (M.H.); Universitäts-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany (F.-J.N.); Charité-Campus Mitte, Berlin, Germany (K.S.); Charité Campus Benjamin Franklin, Berlin, Germany (B.W.); Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands (T.S.); Hospital Clínic, Thorax Institute, Barcelona, Spain (M.S.); IDIBAPS, University of Barcelona, Barcelona, Spain (M.S.); Hospital Puerta de Hierro, Madrid, Spain (J.G.); Polyclinique les Fleurs, Ollioules, France (P.B.); Hospital and University Fribourg, Switzerland (S.C.); University of Montpellier, Montpellier Cedex 5, France (C.P.); Segeberger Kliniken, Bad Segeberg, Germany (G.R.); Semmelweis University Heart and Vascular Center, Budapest, Hungary (B.M.); Universitätsklinikum Rostock, Rostock, Germany (H.S.); Klinikum Nürnberg Süd, Nürnberg, Germany (J.B.); Lucerne Canton Hospital, Lucerne, Switzerland (P.E.); MedStar Health Research Institute, Washington, DC (R.W.); Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland (S.Z., P.J.); and ICPS, Massy, France (T.L.).
Background: Biodegradable polymers for release of antiproliferative drugs from drug-eluting stents aim to improve vascular healing. We assessed noninferiority of a novel ultrathin strut drug-eluting stent releasing sirolimus from a biodegradable polymer (Orsiro, O-SES) compared with the durable polymer Xience Prime everolimus-eluting stent (X-EES) in terms of the primary end point in-stent late lumen loss at 9 months.
Methods And Results: A total of 452 patients were randomly assigned 2:1 to treatment with O-SES (298 patients, 332 lesions) or X-EES (154 patients, 173 lesions) in a multicenter, noninferiority trial.
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
Eur Heart J
May 2015
ISAResearch Center, Deutsches Herzzentrum München, Technische Universität München, Lazarettstr. 36, 80636, Munich, Germany DZHK, Partner Site Munich Heart Alliance, Munich, Germany.
Background: In patients receiving aspirin, the optimal duration of clopidogrel therapy after drug-eluting stent (DES) implantation remains unclear.
Methods: This multicentre, randomized, double-blind, placebo-controlled trial tested the hypothesis that in patients undergoing DES implantation, 6 months of clopidogrel is non-inferior to 12 months in terms of clinical outcomes. At 6 months after DES implantation, patients on clopidogrel were randomly assigned to either a 6-month period of placebo or an additional 6-month period of clopidogrel.
Automated Quantification of Right Ventricular Fat at Contrast-enhanced Cardiac Multidetector CT in Arrhythmogenic Right Ventricular Cardiomyopathy.
Radiology
June 2015
From the Department of Cardiovascular Imaging (H.C., T.A.A., O.C., F.L., M.M.) and Department of Cardiac Pacing and Electrophysiology (A.D., Y.K., F.S., N.D., M. Hocini, M. Haïssaguerre, P.J.), Hôpital Cardiologique Haut Lévêque, CHU/Université de Bordeaux, Avenue Magellan, 33604 Pessac, France; L'Institut de Rythmologie et de Modélisation Cardiaque LIRYC, CHU/Université de Bordeaux/INSERM U1045, Pessac, France (H.C., A.D., Y.K., F.S., N.D., M. Hocini, M. Haïssaguerre, F.L., M.M., P.J.); Arrhythmia Department, University Heart Center, Freiburg-Bad Krozingen, Germany (A.S.J.); and Inria Asclepios Research Team, Sophia Antipolis, France (J.R., M.S.).
Purpose: To evaluate an automated method for the quantification of fat in the right ventricular (RV) free wall on multidetector computed tomography (CT) images and assess its diagnostic value in arrhythmogenic RV cardiomyopathy (ARVC).
Materials And Methods: This study was approved by the institutional review board, and all patients gave informed consent. Thirty-six patients with ARVC (mean age ± standard deviation, 46 years ± 15; seven women) were compared with 36 age- and sex-matched subjects with no structural heart disease (control group), as well as 36 patients with ischemic cardiomyopathy (ischemic group).
Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism.
Eur J Cardiothorac Surg
August 2013
Department of Cardiovascular Surgery, University Heart Center Freiburg-Bad Krozingen, Freiburg, Germany.
Objectives: Oral anticoagulation in mechanical heart valve recipients remains crucial, and vitamin K antagonists (VKA) are still the gold standard. Polymorphisms of vitamin K epoxide oxidase reductase (VKORC) and cytochrome p450 (CYP2C9) were recently found to influence VKA metabolism. We retrospectively investigated the prevalence of these genotypes and associated anticoagulation-related complications in our patients.
View Article and Find Full Text PDF